Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Crohn Disease, Ulcerative Colitis
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate…
- Trial name
- NCT04877990
- Testing
- Deucravacitinib
- Where
- 43 sites in United States, Australia and 14 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Healthy Subjects
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
This study is a first-in-human phase I randomised, double-blind, placebo-controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only)…
- Trial name
- NCT03980080
- Testing
- OSE-127
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- OSE Immunotherapeutics
Ulcerative Colitis
ABTECT - Maintenance
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active…
- Trial name
- NCT05535946
- Testing
- ABX464
- Where
- 413 sites in United States, Argentina and 32 more
- Volunteers
- 1,116 people
- Sponsor
- Abivax S.A.
Ulcerative Colitis
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
As required for new medications approved by the Ministry of Food and Drug Safety, safety and efficacy information should be provided for a minimum of 90 patients treated in the setting of routine practice during 4 years following…
- Trial name
- NCT04071405
- Testing
- Non-intervention
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Pfizer
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.
- Trial name
- NCT01671956
- Testing
- Bertilimumab
- Where
- 6 sites in Israel
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Colitis, Ulcerative
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
The aim of this study was to investigate the safety and efficacy of SPD476 2.4 g/day given twice daily ([BID] ie 1.2 g/day BID) and SPD476 4.8g/day given QD compared to placebo in subjects with acute, mild to moderate ulcerative…
- Trial name
- NCT00503243
- Testing
- Delayed and extended release mesalazine
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Shire
Ulcerative Colitis
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy
The objective of this study is to evaluate the efficacy and the tolerability of oral parnaparin sodium (210mg), administered in extended-release tablets identified as CB-01-05-MMX™.
- Trial name
- NCT00867438
- Testing
- Sigmoidoscopy
- Volunteers
- 133 people
- Sponsor
- Cosmo Technologies Ltd
Ulcerative Colitis
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis
SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of SOR102 (Part 1) and multiple oral doses (Part 2) of…
- Trial name
- NCT06080048
- Testing
- SOR102
- Where
- 2 sites in Georgia, Ukraine
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Sorriso Pharmaceuticals, Inc.
Ulcerative Colitis, Inflammatory Bowel Disease
Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study
To evaluate the safety and efficacy on clinical symptoms, mucosal histology and endoscopic mucosal appearance of two doses of SR140333B against placebo in patients with mild to moderate ulcerative colitis resistant to treatment…
- Trial name
- NICE (NCT00232258)
- Testing
- Nolpitantium besylate
- Where
- 14 sites in Argentina, Belgium and 12 more
- Volunteers
- 307 people
- Sponsor
- Sanofi
Ulcerative Colitis
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis.
- Trial name
- GO-COLITIS (NCT02092285)
- Testing
- Golimumab
- Where
- United Kingdom
- Volunteers
- 205 people
- Sponsor
- Merck Sharp & Dohme LLC
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Ulcerative Colitis
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00744016
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 305 people
- Sponsor
- Bausch Health Americas, Inc.
Inflammatory Bowel Diseases
EURECA (EUropeanRElapseCAlprotectin) Study
This study will investigate the correlation of fecal calprotectin (FC) values to quiescent ulcerative colitis and to disease activity (relapse) as assessed by clinical data and endoscopy.
- Trial name
- NCT05168917
- Testing
- LIAISON Calprotectin
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 225 people
- Sponsor
- DiaSorin Inc.
Ulcerative Colitis
A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis
The purpose of this study is to determine whether a treatment of a novel leukapheresis column is safe and effective in patients with moderate to severe ulcerative colitis.
- Trial name
- NCT01097590
- Testing
- Active TLA Gut™ column
- Where
- Sweden
- Volunteers
- 23 people
- Sponsor
- IBD Column Therapies International AB
Ulcerative Colitis, Crohn's Disease
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon.
- Trial name
- NCT06581042
- Where
- 11 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- AbbVie
Active Ulcerative Colitis
Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled phase II study.
- Trial name
- NCT03235752
- Testing
- TJ301 300mg, TJ301 600mg
- Where
- 27 sites in China, South Korea and 1 more
- Volunteers
- 91 people
- Sponsor
- I-Mab Biopharma HongKong Limited
Ulcerative Colitis
A Comparison of Once a Day Dose Compared to 2 Doses/Day
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
- Trial name
- NCT00505778
- Testing
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Where
- 245 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Warner Chilcott
Colitis, Ulcerative
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- EFFECT-UC (NCT06294925)
- Testing
- Etrasimod
- Where
- 41 sites in Canada, Germany and 1 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
Ulcerative Colitis
FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of the drug OPC-6535 compared to a placebo in patients with active Ulcerative Colitis.
- Trial name
- NCT00064441
- Testing
- OPC-6535 Tablets (drug)
- Where
- 23 sites in United States
- Volunteers
- 375 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis.
- Trial name
- NCT05372939
- Testing
- AMT-101 (oral), Humira (adalimumab)
- Where
- 18 sites in Georgia, Netherlands and 2 more
- Volunteers
- 51 people
- Sponsor
- Applied Molecular Transport